Mass spectrometry-based proteomics of human cannabinoid receptor 2: Covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation

Journal of Proteome Research

Volumn 10, Issue 10, 2011, Pages 4789-4798

  Szymanski, Dennis W ^a   Papanastasiou, Malvina ^a   Melchior, Katja ^a   Zvonok, Nikolai ^a   Mercier, Richard W ^a   Janero, David R ^a   Thakur, Ganesh A ^a   Cha, Sangwon ^a   Wu, Billy ^a   Karger, Barry ^a   Makriyannis, Alexandros ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

agonist; covalent probe; drug discovery; electrospray ionization; GPCR; ligand binding domain; multiple reaction monitoring; protein structural biology

Indexed keywords

AM 841; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CYSTEINE; POLYHISTIDINE TAG; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEOMICS; QUANTITATIVE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; CYSTEINE; EPITOPES; HUMANS; LIGANDS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEOMICS; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS; SPODOPTERA; TETRAHYDROCANNABINOL;

EID: 80053892522     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr2005583     Document Type: Article

References (47)

1. Mouslech, Z.; Valla, V. Endocannabinoid system: an overview of its potential in current medical practice Neuro. Endocrinol. Lett. 2009, 30, 153-179
2. Di Marzo, V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic application Pharmacol. Res. 2009, 60, 77-84
3. Reggio, P. H. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown Curr. Med. Chem. 2010, 17, 1468-1486
4. Demuth, D. G.; Molleman, A. Cannabinoid signaling Life Sci. 2006, 78, 549-563
5. Janero, D. R.; Makriyannis, A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis Expert Opin. Emerg. Drugs 2009, 14, 43-65
6. Janero, D. R.; Vadivel, S. K.; Makriyannis, A. Pharmacotherapeutic modulation of the endocannabinoid signaling system in psychiatric disorders: drug-discovery strategies Int. Rev. Psychiatry 2009, 21, 122-133
7. Kim, K.; Moore, D. H.; Makriyannis, A.; Abood, M. E. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis Eur. J. Pharmacol. 2006, 542, 100-105 (Pubitemid 44096919)
8. Rahn, E. J.; Thakur, G. A.; Wood, J. A.; Zvonok, A. M.; Makriyannis, A.; Hohmann, A. G. Pharmacological characterization of AM1710, a putative cannabinoid CB(2) agonist from the cannabilactone class: antinociception without central nervous system side-effects Pharmacol. Biochem. Behav. 2011, 98, 493-502
9. Gorantla, S.; Makarov, E.; Roy, D.; Finke-Dwyer, J.; Murrin, L. C.; Gendelman, H. E.; Poluektova, L. Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS J. Neuroimmune. Pharmacol. 2010, 5, 456-468
10. Patel, K. D.; Davison, J. S.; Pittman, Q. J.; Sharkey, K. A. Cannabinoid CB(2) receptors in health and disease Curr. Med. Chem. 2010, 17, 1393-1410
11. Patinkin, D.; Milman, G.; Breuer, A.; Fride, E.; Mechoulam, R. Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation Eur. J. Pharmacol. 2008, 595, 1-6
12. Pertwee, R. G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines Br. J. Pharmacol. 2009, 156, 397-411
13. Ashton, J. C.; Wright, J. L.; McPartland, J. M.; Tyndall, J. D. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists Curr. Med. Chem. 2008, 15, 1428-1443 (Pubitemid 351997793)
14. Alkhalfioui, F.; Magnin, T.; Wagner, R. From purified GPCRs to drug discovery: the promise of protein-based methodologies Curr. Opin. Pharmacol. 2009, 9, 629-635
15. Congreve, M.; Marshall, F. The impact of GPCR structures on pharmacology and structure-based drug design Br. J. Pharmacol. 2010, 159, 986-996
16. Poso, A.; Huffmann, J. W. Targeting the cannabinoid CB2 receptor: modeling and structural determinants of CB2 selective ligands Br. J. Pharmacol. 2008, 153, 335-346
17. Tikhonova, I. G.; Costanzi, S. Unraveling the structure and function of G protein-coupled receptors through NMR spectroscopy Curr. Pharm. Des. 2009, 15, 4003-4016
18. Cherezov, A.; Abola, E.; Stevens, R. C. Recent progress in the structure determination of GPCRs, a membrane protein family with high potential as pharmaceutical targets Methods Mol. Biol. 2010, 654, 141-168
19. Zvonok, N.; Yaddanapudi, S.; Williams, J.; Dai, S.; Dong, K.; Rejtar, T.; Karger, B. L.; Makriyannis, A. Comprehensive proteomic mass spectrometric characterization of human cannabinoid CB2 receptor J. Proteome Res. 2007, 6, 2068-2079 (Pubitemid 46985094)
20. Cristalli, G.; Lambertucci, C.; Marucci, G.; Volpini, R.; Dal Ben, D. A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists Curr. Pharm. Des. 2008, 14, 1525-1552 (Pubitemid 351997817)
21. Durdagi, S.; Papadopoulos, M. G.; Zoumpoulakis, P. G.; Kokoulista, C.; Mavromoustakos, T. A computational study on cannabinoid receptors and potent bioactive cannabinoid ligands: homology modeling, docking, de novo drug design and molecular dynamics analysis Mol. Divers. 2010, 14, 257-276
22. McPartland, J. M.; Glass, M.; Pertwee, R. G. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences Br. J. Pharmacol. 2007, 152, 589-593
23. Pei, Y.; Mercier, R. W.; Anday, J. K.; Thakur, G. A.; Zvonok, A. M.; Hurst, D.; Reggio, P. H.; Janero, D. R.; Makriynannis, A. M. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation Chem. Biol. 2008, 15, 1207-1219
24. Tiburu, E. K.; Tyukhtenko, S.; Deshmukh, L.; Vinogradova, O.; Janero, D. R.; Makriyannis, A. Structural biology of human cannabinoid receptor-2 helix 6 in membrane-mimetic environments Biochem. Biophys. Res. Commun. 2009, 384, 243-248
25. Howlett, A. C.; Wilken, G. H.; Pigg, J. J.; Houston, D. B.; Lan, R.; Liu, Q.; Makriyannis, A. Azido- and isothiocayano-substituted aryl pyrazoles bind covalently to the CB1 cannabinoid receptor and impair signal transduction J. Neurochem. 2000, 74, 2174-2181 (Pubitemid 30217675)
26. Zvonok, N.; Pandarinathan, L.; Williams, J.; Johnston, M.; Karageorgos, I.; Janero, D. R.; Krishnan, S. C.; Makriyannis, A. Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectroscopy and mutational analysis Chem. Biol. 2008, 15, 854-862
27. Mercier, R. W.; Pei, Y.; Pandarinathan, L.; Janero, D. R.; Zhang, J.; Makriyannis, A. hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation Chem. Biol. 2010, 17, 1132-1142
28. Ballasteros, J. A.; Weinstein, H. Integrated methods for the construction three dimensional models and computational probing of structure function relations in G protein-coupled receptors. In Methods in Neuroscience; Conn, P. M.; Sealfon, S. M., Eds; Academic Press: San Diego, CA, 1995; Vol. 25, pp 366-428.
29. Baslé, E.; Joubert, N.; Pucheault, M. Protein chemical modification on endogenous amino acids Chem. Biol. 2010, 17, 213-227
30. Filppula, S.; Yaddanapudi, S.; Mercier, R.; Xu, W.; Pavlopoulos, S.; Cai, J.; Pierce, W. M.; Markiyannis, A. Purification and mass spectroscopic analysis of human CB2 cannabinoid receptor expressed in baculovirus system J. Peptide Res. 2004, 64, 225-236 (Pubitemid 40040854)
31. Yocum, A. K.; Chinnaiyan, A. M. Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry Brief Funct. Genomic Proteomic 2008, 8, 145-157
32. Kyle, J.; Doolittle, R. F. A simple method for displaying the hydropathic character of a protein J. Mol. Biol. 1982, 157, 105-132
33. Chiu, M.; Tsang, C.; Grihalde, N.; MacWIlliams, M. P. Over-expression, solubilization, and purification of G protein-coupled receptors for structural biology Comb. Chem. High Throughput Screen. 2008, 11, 439-462 (Pubitemid 351969361)
34. Sarramenga, V.; Muller, I.; Milon, A.; Talmont, F. Recombinant G protein-coupled receptors from expression to renaturation: a challenge toward structure Cell. Mol. Life Sci. 2006, 63, 1149-1164 (Pubitemid 43939002)
35. Block, H.; Maertens, B.; Spriestersbach, A.; Brinker, N.; Kubicek, J.; Fabis, R.; Labahn, J.; Schäfer, F. Immobilized-metal affinity chromatography (IMAC): a review Methods Enzymol. 2009, 463, 439-473
36. Wager-Miller, J.; Westenbroek, R; Mackie, K. Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example Chem. Phys. Lipids 2002, 121, 83-89 (Pubitemid 36044545)
37. 2A adenosine receptor Biochim. Biophys. Acta 2011, 1808, 1256-1266
38. Kristiansen, K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function Pharmacol. Ther. 2004, 103, 21-80 (Pubitemid 38891912)
39. Cutillas, P. R.; Timms, J. F. Approaches and applications of quantitative LC-MS for proteomics and activitomics Methods Mol. Biol. 2010, 658, 3-17
40. Picone, R. P.; Khanolkar, A. D.; Wei, X.; Ayotte, L. A.; Thakur, G. A.; Hurst, D. P.; Abood, M. E.; Reggio, P. H.; Fournier, D. J.; Makriyannis, A. (-)-7′-Isothiocyanato-11-hydroxy-1′,1′- dimethylheptylhexahydrocannabinol (AM-841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor Mol. Pharmacol. 2005, 68, 1623-1635 (Pubitemid 41654346)
41. Grisshammer, R. Purification of recombinant G-protein-coupled receptors Methods Enzymol. 2009, 463, 631-645
42. Kuzyk, M. A.; Smith, D.; Yang, J.; Cross, T. J.; Jackson, A. M.; Hardie, D. B.; Anderson, N. L.; Borchers, C. H. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma Mol. Cell. Proteomics 2009, 8, 1860-1877
43. Kitteringham, N. R.; Jenkins, R. E.; Lane, C. S.; Elliot, V. L.; Park, B. K. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics J. Chromatogr. B 2009, 877, 1229-1239
44. Nettleship, J. E.; Assenberg, R.; Diprose, J. M.; Rahman-Huq, N.; Owens, R. J. Recent advances in the production of proteins in insect and mammalian cells for structural biology J. Struct. Biol. 2010, 172, 55-65
45. Christoffers, K. H.; Li, H.; Keenan, S. M.; Howells, R. D. Purification and mass spectrometric analysis of the mu opioid receptor Brain Res. Mol. Brain Res. 2003, 118, 119-131 (Pubitemid 37238994)
46. Holst, B.; Nygaard, R.; Valentin-Hansen, L.; Bach, A.; Engelstoft, M. S.; Petersen, P. S.; Frimurer, T. M.; Schwartz, T. W. A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors J. Biol. Chem. 2010, 285, 3973-3985
47. Langelaan, D. N.; Ngweniform, P.; Rainey, J. K. Biophysical characterization of G-protein coupled receptor-peptide ligand binding Biochem. Cell Biol. 2011, 89, 98-105